<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01658228</url>
  </required_header>
  <id_info>
    <org_study_id>#6459</org_study_id>
    <secondary_id>R01AG040093-01</secondary_id>
    <nct_id>NCT01658228</nct_id>
  </id_info>
  <brief_title>Combination Treatment Study for Memory Impairment and Depression</brief_title>
  <acronym>DEP-CI</acronym>
  <official_title>Pilot Combination Treatment Trial of Mild Cognitive Impairment With Depression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York State Psychiatric Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>New York State Psychiatric Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients presenting with depression (DEP) and cognitive impairment (CI), represent a unique,
      understudied population that is difficult to diagnose, treat and estimate prognosis. Our
      pilot data, supported by the literature, suggest that many DEP-CI patients show cognitive
      decline and often convert to dementia, primarily Alzheimer's disease (AD). In DEP-CI, there
      is a lack of data on treatment response of mood symptoms to antidepressant treatment and
      particularly of cognitive deficits to cognitive enhancer treatment. Our initial pilot data in
      a double-blind study showed that donepezil was superior to placebo in improving memory in
      antidepressant-treated DEP-CI patients. In a second pilot study, open label es-citalopram
      plus memantine treatment led to a low rate of conversion to dementia.

      In this proposed pilot clinical trial, the investigators will evaluate, treat and follow a
      broad sample of 80 DEP-CI patients at NYSPI/Columbia University Medical Center (N = 40) and
      Duke University Medical Center (N = 40). Recruitment will be from clinics and/or
      advertisements. In the treatment protocol, all 80 DEP-CI patients will receive baseline mood
      and memory assessments and open antidepressant treatment with citalopram for 8 weeks. At 8
      weeks, repeat assessment will occur and patients whose depression has responded to citalopram
      will be randomized to add-on donepezil or placebo. Non-responders to citalopram will receive
      open treatment with venlafaxine and will be randomized 8 weeks later (16 weeks of open
      antidepressant treatment) to add-on donepezil or placebo. Patients will be followed for a
      total period of 18 months with continuous open antidepressant treatment during the trial.

      Donepezil is being studied in order to increase the likelihood of obtaining a signal. If the
      results are positive, the investigators can begin clarifying the mechanism(s) in subsequent
      trials. Baseline apolipoprotein E e4 genotype, odor identification deficits, and MRI
      hippocampal and entorhinal cortex atrophy will be explored as predictors of donepezil
      response in the 18-month trial. Improving cognition and delaying conversion to a clinical
      diagnosis of dementia in this high risk group will enhance quality of life, reduce family
      burden, and markedly diminish overall health care costs.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In the elderly, the most common neuropsychiatric disorders are depression (DEP) and cognitive
      impairment (CI). Their co-occurrence (DEP-CI) may exceed chance. The lack of research in
      DEP-CI, the need to determine early prognostic indicators, and to develop optimal treatment
      strategies, was emphasized by a NIH consensus panel. Since depression in patients with CI
      increases the risk of conversion to dementia, treatment strategies for DEP-CI have
      longer-term implications beyond acute antidepressant treatment response. However, in DEP-CI,
      there is a lack of data on treatment response of mood symptoms to antidepressant treatment
      and of cognitive deficits to cognitive enhancer treatment, and the long-term prognosis in
      these patients remains unclear. The investigators have initial pilot data showing that
      donepezil was superior to placebo in improving memory performance in DEP-CI patients, and
      pilot data showing that patients with DEP-CI treated with combined escitalopram and memantine
      have a low conversion rate to dementia, primarily Alzheimer's disease (AD), over one year.
      This proposal is for the first study to explicitly examine cognitive change, including
      conversion to dementia, in a randomized, double-blind, placebo-controlled donepezil treatment
      trial in DEP-CI patients treated openly with antidepressants. The investigators will conduct
      systematic follow-up to evaluate 18-month outcome. In addition to apolipoprotein E ε4
      genotype, the investigators will explore MRI hippocampal and entorhinal cortex atrophy and
      odor identification deficits as biomarkers that moderate response.

      This pilot trial will enroll about 80 DEP-CI patients who present to the departments of
      Psychiatry, Neurology and Internal Medicine at NYSPI/Columbia University and Duke University
      medical centers, ensuring broad representation for clinical relevance. In the treatment
      protocol, all 80 DEP-CI patients will receive open antidepressant treatment with citalopram
      for 8 weeks. At 8 weeks, citalopram responders will continue to be treated on citalopram,
      while non-responders will switch to venlafaxine treatment for an additional 8 weeks. At 16
      weeks, all subjects will be randomized to add-on donepezil or placebo (N.B. Patients with a
      prior history of nonresponse to both citalopram and venlafaxine will be enrolled in the
      protocol and treated with bupropion and subsequently with doctor's choice of antidepressant).
      Patients will be followed for a total period of up to 18 months in the trial, with
      antidepressant treatment adjusted as needed based on clinical response and side effects,
      i.e., open antidepressant treatment is continuous for all subjects throughout the trial and
      is not the experimental intervention. The investigators chose to study antidepressant plus
      donepezil compared to placebo based on our pilot data and to increase the likelihood of
      obtaining a signal.

      Aim 1 (primary aim of the study). To assess change in cognitive status over 18 months in
      antidepressant-treated DEP-CI patients comparing donepezil to placebo.

      Hypothesis 1. Antidepressant-treated DEP-CI patients on donepezil will show a lower rate of
      conversion to dementia, primarily AD, compared to antidepressant-treated DEP-CI patients on
      placebo by the end of the 18-month trial.

      Hypothesis 2 (secondary). Compared to the placebo group, the donepezil group will show better
      cognitive outcome by the end of the 18-month trial (SRT total recall: primary measure;
      modified ADAS-cog: secondary measure).

      Hypothesis 3 (secondary). At the end of 24 weeks on add-on donepezil or placebo, the
      donepezil group will show better cognitive outcome than placebo (SRT total recall: primary
      measure; modified ADAS-cog: secondary measure).

      Aim 2: To evaluate moderators of treatment on cognitive change in the 18-month
      donepezil-placebo trial, based on the view that patients with incipient AD brain pathology
      will have superior cognitive outcome on donepezil. These Aim 2 hypotheses are considered
      exploratory.

      Hypothesis 1. Patients with the apolipoprotein E ε4 allele (homozygote or heterozygote),
      compared to patients without this allele, will have better cognitive outcome on donepezil
      compared to placebo.

      Hypothesis 2. Lower scores on the UPSIT (odor identification test) at baseline will be
      associated with better cognitive outcome on donepezil compared to placebo.

      Hypothesis 3. Smaller MRI hippocampal and entorhinal cortex volumes (atrophy) will be
      associated with better cognitive outcome on donepezil compared to placebo.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">January 2016</completion_date>
  <primary_completion_date type="Actual">January 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Selective Reminding Test (SRT) Total Recall</measure>
    <time_frame>Week 16</time_frame>
    <description>The 12-item, 6-trial SRT is a memory measure used to assess verbal list learning and memory. The total number of words learned over six trials (total immediate recall) was obtained.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Selective Reminding Test (SRT) Delayed Recall</measure>
    <time_frame>Week 16</time_frame>
    <description>The 12-item, 6-trial SRT is a memory measure used to assess verbal list learning and memory. The total number of words learned over six trials (total immediate recall) and delayed recall (after a 15-minute delay) was obtained.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Alzheimer's Disease Assessment Scale - Cognitive (ADAS-Cog)</measure>
    <time_frame>Week 16</time_frame>
    <description>The modified ADAS-Cog is a cognitive battery that assesses learning, memory, language production, language comprehension, constructional praxis, ideational praxis, and orientation. Subjects' scores represent the total number of errors made throughout the various tasks. The total number of possible errors is between 0-85.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>WMS-III Visual Reproduction Subtest</measure>
    <time_frame>Screen (Week 0), Week 16, Week 40, Week 64, Week 78</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Trails A and B</measure>
    <time_frame>Screen (Week 0), Week 16, Week 40, Week 64, Week 78</time_frame>
    <description>Parts A and B are composed of 25 circles. Patients are asked to scan the entire page and identify the next number or letter in a sequence.</description>
  </other_outcome>
  <other_outcome>
    <measure>Stroop</measure>
    <time_frame>Screen (Week 0), Week 16, Week 40, Week 64, Week 78</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>WAIS-III Digit Symbol Subtest</measure>
    <time_frame>Screen (Week 0), Week 16, Week 40, Week 64, Week 78</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>WAIS-III Block Design Subtest</measure>
    <time_frame>Screen (Week 0), Week 16, Week 40, Week 64, Week 78</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>COWAT</measure>
    <time_frame>Screen (Week 0), Week 16, Week 40, Week 64, Week 78</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Boston Naming</measure>
    <time_frame>Screen (Week 0), Week 16, Week 40, Week 64, Week 78</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Apolipoprotein E Genotype</measure>
    <time_frame>Week 2</time_frame>
    <description>Using a standard protocol, DNA is amplified by the polymerase chase reaction (PCR). The genotypes are determined blind to subject status (patient or control) by the sizes of DNA fragments present.</description>
  </other_outcome>
  <other_outcome>
    <measure>University of Pennsylvania Smell Identification Test (UPSIT)</measure>
    <time_frame>Screen (Week 0)</time_frame>
    <description>The subject will &quot;scratch and sniff&quot; 40 common odorants embedded in microcapsules on a separate page. The subject will choose the answer from a 4-item multiple choice list. Scores will range from 0-40.</description>
  </other_outcome>
  <other_outcome>
    <measure>MRI Scan</measure>
    <time_frame>Within 1 month of Screen Visit (Week 0)</time_frame>
    <description>Images will be obtained using a GE Signa 3 Tesla whole body scanner. T1-weighted sagittal fspgr and T2 FLAIR are the pulse sequences used in order to obtain the MRI images.</description>
  </other_outcome>
  <other_outcome>
    <measure>WMS-R Logical Memory</measure>
    <time_frame>Week 0 Screening</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>FC-SRT</measure>
    <time_frame>Week 0 Screening</time_frame>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">86</enrollment>
  <condition>Depression</condition>
  <condition>Mild Cognitive Impairment</condition>
  <arm_group>
    <arm_group_label>Donepezil Treatment Group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>For the initial 16 weeks of open-label antidepressant treatment, citalopram up to 20 mg daily or venlafaxine up to 225 mg daily was prescribed. At 16 weeks, all patients were randomized, double-blind, to add-on donepezil or placebo for 62 weeks. Donepezil was started at 5 mg and increased to 10 mg daily or maximum tolerated dose while continuing antidepressants.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Treatment Group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>For the initial 16 weeks of open-label antidepressant treatment, citalopram up to 20 mg daily or venlafaxine up to 225 mg daily was prescribed. At 16 weeks, all patients were randomized, double-blind, to add-on donepezil or placebo for 62 weeks. Placebo dose was increased during the study to match Donepezil dose increases while continuing antidepressants.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Citalopram</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>An open treatment 8 week flexible dosing schedule starting with citalopram 10mg/day for the first week, then increasing to 20 mg/day thereafter to treat the depression. At the week 8 visit, citalopram responders will continue citalopram treatment and will be randomized to add-on donepezil or placebo at the week 16 visit.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Venlafaxine</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>For patients who did not respond to citalopram, open treatment 8 week flexible dosing schedule starting with venlafaxine 37.5mg/day for the first week, then 75mg/day for the second week, then 150mg/day for the third and fourth week, then 225mg/day for the fifth through eighth weeks. At the end of the eighth week, we will assess patients for antidepressant response. At this time-point, venlafaxine responders will be randomized to add-on donepezil or placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Donepezil</intervention_name>
    <description>Donepezil 5mg will be given for 6 weeks and if tolerated, the dose will be increased to 10 mg per day. The dose range of 5 to 10 mg per day is the recommended dose for donepezil in the treatment of mild to moderate Alzheimer's disease.</description>
    <arm_group_label>Donepezil Treatment Group</arm_group_label>
    <other_name>Aricept</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>A placebo capsule will be given to randomized subjects for the starting at week 16 and continuing for the remainder of the study. This group will not receive donepezil as treatment.</description>
    <arm_group_label>Placebo Treatment Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Citalopram</intervention_name>
    <description>Citalopram tablet will be given to subjects during an 8 week flexible dosing open treatment. If subjects respond to citalopram treatment they will be randomized to add-on donepezil/placebo.</description>
    <arm_group_label>Citalopram</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Venlafaxine</intervention_name>
    <description>Venlafaxine tablet will be given to subjects during an 8 week flexible dosing open treatment if they did not respond to citalopram. If subjects respond to venlafaxine treatment they will be randomized to add-on donepezil/placebo.</description>
    <arm_group_label>Venlafaxine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Of either sex, age 55-95 years old with minimum 8 years of education who meet criteria
             for both depression and cognitive impairment as described below.

          -  Study Criteria for &quot;depression&quot;:

             i. Patients who meet DSM-IV symptom criteria for Major Depression or Dysthymia for a
             minimum of 6 months (2 year duration DSM-IV TR criterion not required for dysthymic
             disorder in this study). ii. 24-item HAM-D ≥14.

          -  Study Criteria for &quot;cognitive impairment&quot;:

             i. Subjective memory or other cognitive complaints. ii. Score ≤ 11 on the Logical
             Memory II (Delayed Paragraph Recall, Paragraph A) test from the Wechsler Memory Scale
             - Revised OR a score that is ≥ 1.5 standard deviations below the norms on the FC SRT

          -  Folstein Mini Mental State (MMSE) score ≥ 21 out of 30.

          -  Clinical Dementia Rating (CDR) of 0.5 on the memory item and global rating of 0.5
             indicating questionable dementia

          -  Willing and capable of giving informed consent

          -  A family member or close friend who consents to serve as informant during the study;
             this can be a telephone informant in the case of patients who do not have a live-in
             informant or close significant other.

        Exclusion Criteria:

          -  Meets Criteria for dementia (DSM-IV) or probable Alzheimer's disease (NINCDS-ADRDA
             criteria)

          -  Meets DSM IV TR criteria for:

               1. schizophrenia, schizoaffective disorder, psychotic depression or other psychosis,
                  or bipolar I disorder

               2. alcohol or substance dependence or abuse (current or within past 6 months)

          -  Active suicidal ideation or suicidal attempt in last 6 months.

          -  Clinical stroke with residual neurological deficits.

          -  Use of medications known to have a negative impact on cognition: benzodiazepines in
             lorazepam equivalents ≥ 2 mg daily, narcotics, or anticholinergics. (N.B. Medications
             that may be associated with cognitive impairment but are rarely considered the likely
             etiology, e.g, theophylline, nifedipine, Beta blockers, will not be excluded.)

          -  An acute, severe or unstable medical condition. For cancer, acutely ill patients
             (including those with metastases) are excluded, but past history of successfully
             treated cancer does not result in exclusion.

          -  Presence of any of the following disorders: a) CNS infection, with CSF evidence of
             meningitis, encephalitis, or other infectious process; b) Post-traumatic dementia,
             defined as dementia with a clear temporal relationship to a severe head injury where
             consciousness was lost; c) Huntington's disease; d) Multiple sclerosis; e) Parkinson's
             disease; f) Other neurologic disorders with focal signs, e.g., amyotrophic lateral
             sclerosis; g) Mental retardation.

          -  Contra-indication to MRI scan: pacemaker, metal implants following surgery, any other
             contraindication to MRI (e.g., ferromagnetic aneurysm clips, heart valves). For
             patients with possible claustrophobia, they can do the MRI with adjunct lorazepam 0.5
             mg to reduce anxiety. Patients who cannot do the MRI scan will still be eligible for
             the clinical trial, i.e., MRI is optional.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>95 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Davangere Devanand, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gregory Pelton, MD</last_name>
    <role>Study Director</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Steven Roose, MD</last_name>
    <role>Study Director</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Murali Doraiswamy, MD</last_name>
    <role>Study Director</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>New York State Psychiatric Institute</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 30, 2012</study_first_submitted>
  <study_first_submitted_qc>August 1, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 6, 2012</study_first_posted>
  <results_first_submitted>August 7, 2017</results_first_submitted>
  <results_first_submitted_qc>October 16, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">October 17, 2017</results_first_posted>
  <last_update_submitted>October 16, 2017</last_update_submitted>
  <last_update_submitted_qc>October 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Depression</keyword>
  <keyword>Dysthymia</keyword>
  <keyword>Cognitive Impairment</keyword>
  <keyword>Cognitive Decline</keyword>
  <keyword>Memory</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Donepezil</mesh_term>
    <mesh_term>Dexetimide</mesh_term>
    <mesh_term>Venlafaxine Hydrochloride</mesh_term>
    <mesh_term>Citalopram</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were recruited from clinics and/or advertisements.</recruitment_details>
      <pre_assignment_details>86 subjects were enrolled in the open treatment phase of the study and then 61 subjects were randomized at 16 weeks to the add-on donepezil/placebo treatment groups.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Donepezil Treatment Group</title>
          <description>For the initial 16 weeks of open-label antidepressant treatment, citalopram up to 20 mg daily or venlafaxine up to 225 mg daily was prescribed. At 16 weeks, all patients were randomized, double-blind, to add-on donepezil or placebo for 62 weeks. Donepezil was started at 5 mg and increased to 10 mg daily or maximum tolerated dose while continuing antidepressants.</description>
        </group>
        <group group_id="P2">
          <title>Placebo Treatment Group</title>
          <description>For the initial 16 weeks of open-label antidepressant treatment, citalopram up to 20 mg daily or venlafaxine up to 225 mg daily was prescribed. At 16 weeks, all patients were randomized, double-blind, to add-on donepezil or placebo for 62 weeks. Placebo dose was increased during the study to match Donepezil dose increases while continuing antidepressants.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Donepezil Treatment Group</title>
          <description>For the initial 16 weeks of open-label antidepressant treatment, citalopram up to 20 mg daily or venlafaxine up to 225 mg daily was prescribed. At 16 weeks, all patients were randomized, double-blind, to add-on donepezil or placebo for 62 weeks. Donepezil was started at 5 mg and increased to 10 mg daily or maximum tolerated dose while continuing antidepressants.
Donepezil: Donepezil 5mg will be given for 6 weeks and if tolerated, the dose will be increased to 10 mg per day. The dose range of 5 to 10 mg per day is the recommended dose for donepezil in the treatment of mild to moderate Alzheimer's disease.</description>
        </group>
        <group group_id="B2">
          <title>Placebo Treatment Group</title>
          <description>For the initial 16 weeks of open-label antidepressant treatment, citalopram up to 20 mg daily or venlafaxine up to 225 mg daily was prescribed. At 16 weeks, all patients were randomized, double-blind, to add-on donepezil or placebo for 62 weeks. Placebo dose was increased during the study to match Donepezil dose increases while continuing antidepressants.
Placebo: A placebo capsule will be given to randomized subjects for the starting at week 16 and continuing for the remainder of the study. This group will not receive donepezil as treatment.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
            <count group_id="B2" value="31"/>
            <count group_id="B3" value="61"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67.1" spread="7.7"/>
                    <measurement group_id="B2" value="72.4" spread="8.9"/>
                    <measurement group_id="B3" value="69.8" spread="8.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Selective Reminding Test (SRT) Total Recall</title>
        <description>The 12-item, 6-trial SRT is a memory measure used to assess verbal list learning and memory. The total number of words learned over six trials (total immediate recall) was obtained.</description>
        <time_frame>Week 16</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Donepezil Treatment Group</title>
            <description>For the initial 16 weeks of open-label antidepressant treatment, citalopram up to 20 mg daily or venlafaxine up to 225 mg daily was prescribed. At 16 weeks, all patients were randomized, double-blind, to add-on donepezil or placebo for 62 weeks. Donepezil was started at 5 mg and increased to 10 mg daily or maximum tolerated dose while continuing antidepressants.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Treatment Group</title>
            <description>For the initial 16 weeks of open-label antidepressant treatment, citalopram up to 20 mg daily or venlafaxine up to 225 mg daily was prescribed. At 16 weeks, all patients were randomized, double-blind, to add-on donepezil or placebo for 62 weeks. Placebo dose was increased during the study to match Donepezil dose increases while continuing antidepressants.</description>
          </group>
        </group_list>
        <measure>
          <title>Selective Reminding Test (SRT) Total Recall</title>
          <description>The 12-item, 6-trial SRT is a memory measure used to assess verbal list learning and memory. The total number of words learned over six trials (total immediate recall) was obtained.</description>
          <units>Words</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.6" spread="11.2"/>
                    <measurement group_id="O2" value="46.6" spread="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Selective Reminding Test (SRT) Delayed Recall</title>
        <description>The 12-item, 6-trial SRT is a memory measure used to assess verbal list learning and memory. The total number of words learned over six trials (total immediate recall) and delayed recall (after a 15-minute delay) was obtained.</description>
        <time_frame>Week 16</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Donepezil Treatment Group</title>
            <description>For the initial 16 weeks of open-label antidepressant treatment, citalopram up to 20 mg daily or venlafaxine up to 225 mg daily was prescribed. At 16 weeks, all patients were randomized, double-blind, to add-on donepezil or placebo for 62 weeks. Donepezil was started at 5 mg and increased to 10 mg daily or maximum tolerated dose while continuing antidepressants.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Treatment Group</title>
            <description>For the initial 16 weeks of open-label antidepressant treatment, citalopram up to 20 mg daily or venlafaxine up to 225 mg daily was prescribed. At 16 weeks, all patients were randomized, double-blind, to add-on donepezil or placebo for 62 weeks. Placebo dose was increased during the study to match Donepezil dose increases while continuing antidepressants.</description>
          </group>
        </group_list>
        <measure>
          <title>Selective Reminding Test (SRT) Delayed Recall</title>
          <description>The 12-item, 6-trial SRT is a memory measure used to assess verbal list learning and memory. The total number of words learned over six trials (total immediate recall) and delayed recall (after a 15-minute delay) was obtained.</description>
          <units>Words</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.4" spread="3"/>
                    <measurement group_id="O2" value="7.4" spread="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Alzheimer's Disease Assessment Scale - Cognitive (ADAS-Cog)</title>
        <description>The modified ADAS-Cog is a cognitive battery that assesses learning, memory, language production, language comprehension, constructional praxis, ideational praxis, and orientation. Subjects' scores represent the total number of errors made throughout the various tasks. The total number of possible errors is between 0-85.</description>
        <time_frame>Week 16</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Donepezil Treatment Group</title>
            <description>For the initial 16 weeks of open-label antidepressant treatment, citalopram up to 20 mg daily or venlafaxine up to 225 mg daily was prescribed. At 16 weeks, all patients were randomized, double-blind, to add-on donepezil or placebo for 62 weeks. Donepezil was started at 5 mg and increased to 10 mg daily or maximum tolerated dose while continuing antidepressants.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Treatment Group</title>
            <description>For the initial 16 weeks of open-label antidepressant treatment, citalopram up to 20 mg daily or venlafaxine up to 225 mg daily was prescribed. At 16 weeks, all patients were randomized, double-blind, to add-on donepezil or placebo for 62 weeks. Placebo dose was increased during the study to match Donepezil dose increases while continuing antidepressants.</description>
          </group>
        </group_list>
        <measure>
          <title>Alzheimer's Disease Assessment Scale - Cognitive (ADAS-Cog)</title>
          <description>The modified ADAS-Cog is a cognitive battery that assesses learning, memory, language production, language comprehension, constructional praxis, ideational praxis, and orientation. Subjects' scores represent the total number of errors made throughout the various tasks. The total number of possible errors is between 0-85.</description>
          <units>number of errors on a scale from 0-85</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.2" spread="6.6"/>
                    <measurement group_id="O2" value="13.9" spread="7.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>WMS-III Visual Reproduction Subtest</title>
        <time_frame>Screen (Week 0), Week 16, Week 40, Week 64, Week 78</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Trails A and B</title>
        <description>Parts A and B are composed of 25 circles. Patients are asked to scan the entire page and identify the next number or letter in a sequence.</description>
        <time_frame>Screen (Week 0), Week 16, Week 40, Week 64, Week 78</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Stroop</title>
        <time_frame>Screen (Week 0), Week 16, Week 40, Week 64, Week 78</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>WAIS-III Digit Symbol Subtest</title>
        <time_frame>Screen (Week 0), Week 16, Week 40, Week 64, Week 78</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>WAIS-III Block Design Subtest</title>
        <time_frame>Screen (Week 0), Week 16, Week 40, Week 64, Week 78</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>COWAT</title>
        <time_frame>Screen (Week 0), Week 16, Week 40, Week 64, Week 78</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Boston Naming</title>
        <time_frame>Screen (Week 0), Week 16, Week 40, Week 64, Week 78</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Apolipoprotein E Genotype</title>
        <description>Using a standard protocol, DNA is amplified by the polymerase chase reaction (PCR). The genotypes are determined blind to subject status (patient or control) by the sizes of DNA fragments present.</description>
        <time_frame>Week 2</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>University of Pennsylvania Smell Identification Test (UPSIT)</title>
        <description>The subject will &quot;scratch and sniff&quot; 40 common odorants embedded in microcapsules on a separate page. The subject will choose the answer from a 4-item multiple choice list. Scores will range from 0-40.</description>
        <time_frame>Screen (Week 0)</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>MRI Scan</title>
        <description>Images will be obtained using a GE Signa 3 Tesla whole body scanner. T1-weighted sagittal fspgr and T2 FLAIR are the pulse sequences used in order to obtain the MRI images.</description>
        <time_frame>Within 1 month of Screen Visit (Week 0)</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>WMS-R Logical Memory</title>
        <time_frame>Week 0 Screening</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>FC-SRT</title>
        <time_frame>Week 0 Screening</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Donepezil Treatment Group</title>
          <description>For the initial 16 weeks of open-label antidepressant treatment, citalopram up to 20 mg daily or venlafaxine up to 225 mg daily was prescribed. At 16 weeks, all patients were randomized, double-blind, to add-on donepezil or placebo for 62 weeks. Donepezil was started at 5 mg and increased to 10 mg daily or maximum tolerated dose while continuing antidepressants.</description>
        </group>
        <group group_id="E2">
          <title>Placebo Treatment Group</title>
          <description>For the initial 16 weeks of open-label antidepressant treatment, citalopram up to 20 mg daily or venlafaxine up to 225 mg daily was prescribed. At 16 weeks, all patients were randomized, double-blind, to add-on donepezil or placebo for 62 weeks. Placebo dose was increased during the study to match Donepezil dose increases while continuing antidepressants.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac Stents</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Atrial Flutter</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Parkinson's Disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Leg Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Colorectal Cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic Reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Accidental Injury to Left Arm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Polymyalgia Rheumatica</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Right Upper Rotator Cuff Repair</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Biceps Tendinopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Panic Attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Fugue State</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Disorientation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Kidney Stones</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Perirectal Abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>High Blood Pressure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Nasal Congestion</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Sore Throat</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Fatigue/Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Shingles</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Elevated Temperature</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Akathisia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Sweating</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Hot Flashes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Flu</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Bruxism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper Respiratory Infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Sinus Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Ear Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Poison Ivy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Fungus on Toes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Vaginal Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Broken Knee</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Broken 4th Finger</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Right Ankle Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Headache/Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Upset Stomach</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Restless Leg</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>GI Reflux</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Weight Loss</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Bloating</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Decreased Appetite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Increased Weight</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Increased Appetite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle Cramps</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Knee Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Herniated Disk in Neck</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Hip Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Knee Inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Unsteadiness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Lower extremity neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Nightmares</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>UTI</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Davangere Devanand</name_or_title>
      <organization>New York State Psychiatric Institute</organization>
      <phone>646-774-8658</phone>
      <email>dpd3@cumc.columbia.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

